CIK 0000812796
- Non-accelerated filer
- Smaller reporting company
SOLIGENIX, INC.
Sign in to watch- Ticker
- SNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 411505029
- Phone
- +1 609-538-8200
- Business address
- 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540
- Former names
- SOLIGENIX, INC., DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-05-19 | Warusz Joseph Michael VP of Admin, Controller / PAO | Exercise or conversion | +4,690 | $0.64 | $3K | 4,690 |
| 2014-05-19 | Warusz Joseph Michael VP of Admin, Controller / PAO | Exercise or conversion · Option (Right to Buy) | −4,690 | 25,310 | ||
| 2014-05-14 | Brownlie Keith L Director | Exercise or conversion | +16,667 | $0.30 | $5K | 35,714 |
| 2014-05-14 | Brownlie Keith L Director | Exercise or conversion · Option (Right to Buy) | −16,667 | 8,333 | ||
| 2014-05-13 | SCHABER CHRISTOPHER J Chairman, CEO and President | Exercise or conversion | +7,815 | $0.64 | $5K | 67,496 |
| 2014-05-13 | SCHABER CHRISTOPHER J Chairman, CEO and President | Exercise or conversion · Option (Right to Buy) | −7,815 | 112,185 | ||
| 2014-01-06 | Straube Richard Senior VP & CMO | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2013-12-05 | Warusz Joseph Michael VP of Finance and Acting CFO | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2013-12-05 | SCHABER CHRISTOPHER J Chairman, CEO and President | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2013-12-05 | Brughera Marco Maria Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2013-12-05 | BREY ROBERT N Chief Scientific Off., Sr. VP | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2013-09-27 | LAPOINTE ANTHONY GREGG Director | Grant or award · Stock Option (Right to Buy) | +13,275 | 13,275 | ||
| 2013-09-27 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +13,275 | 13,275 | ||
| 2013-09-27 | RUBIN ROBERT J. Director | Grant or award · Stock Option (Right to Buy) | +13,275 | 13,275 | ||
| 2013-09-27 | Brownlie Keith L Director | Grant or award · Stock Option (Right to Buy) | +13,275 | 13,275 | ||
| 2013-09-25 | Warusz Joseph Michael VP of Finance & Acting CFO | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2013-09-25 | SCHABER CHRISTOPHER J Chairman, CEO & President | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2013-09-25 | HORGAN KEVIN Chief Medical Officer & Sr. VP | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2013-09-25 | BREY ROBERT N Chief Scientific Offr & Sr. VP | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2013-06-25 | ZELDIS JEROME B Director | Purchase | +23,809 | $1.05 | $25K | 48,809 |
Page 12 of 14 · 277 trades